Printer Friendly

Access BIO to support clinical advancement of disc stem cell program.

JUPITER, Fla., October 9, 2014--BioRestorative Therapies, Inc.(BRTX) has hired Access BIO, L.C. to provide strategic preclinical and regulatory consulting services related to the company's brtxDISC program.

Initially Access BIO will help the company prepare for pre-Investigational New Drug (IND) and TND meetings with the U.S. Food and Drug Administration (FDA).

brtxDISC (Disc Implanted Stem Cells) is an investigational non-surgical treatment for protruding and bulging lumbar.

The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.


COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Stem Cell Lab World
Date:Oct 20, 2014
Previous Article:First patient treated in neuralstem phase 1 spinal cord injury stem cell trial.
Next Article:Human stem cell patent challenge reaches Supreme Court.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |